Patents by Inventor Ravi Kumar Jalluri

Ravi Kumar Jalluri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tertiary alcohols as PI3K-? inhibitors
    Patent number: 12516065
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: February 1, 2024
    Date of Patent: January 6, 2026
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • COMPOUNDS FOR FGFR INHIBITION
    Publication number: 20250270211
    Abstract: A compound having the following structure of Formula (IV): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Application
    Filed: May 13, 2025
    Publication date: August 28, 2025
    Inventors: Jay Bradford Fell, John E. Robinson, John P. Fischer, Logan E. Vine, Martha E. Rodriguez, Jennifer Fulton, Tanna Bettendorf, Bradley J. Newhouse, Robert A. Rieger, Cori A. Malinky, Aaron Christopher Smith, Ravi Kumar Jalluri, Mark Joseph Chicarelli, Leah J. Salituro, Macedonio J. Mejia
  • Compounds for FGFR inhibition
    Patent number: 12351581
    Abstract: A compound having the following structure of Formula (IV): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Grant
    Filed: August 19, 2024
    Date of Patent: July 8, 2025
    Assignee: Cogent Biosciences, Inc.
    Inventors: Jay Bradford Fell, John E. Robinson, John P. Fischer, Logan E. Vine, Martha E. Rodriguez, Jennifer Fulton, Tanna Bettendorf, Bradley J. Newhouse, Robert A. Rieger, Cori A. Malinky, Aaron Christopher Smith, Ravi Kumar Jalluri, Mark Joseph Chicarelli, Leah J. Salituro, Macedonio J. Mejia
  • PI3K INHIBITORS
    Publication number: 20250206752
    Abstract: A compound having the following structure of Formula (I): or a stereoisomer of the compound, tautomer of the compound, pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, A, X, Z, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Application
    Filed: February 7, 2025
    Publication date: June 26, 2025
    Inventors: Payal Chatterjee, Mark J. Chicarelli, Michael L. Conner, John Fischer, Jennifer Fulton, Ravi Kumar Jalluri, Hailey J. Knox, Vijay Kumar, Bradley J. Newhouse, Martha E. Rodriguez, Leah J. Salituro, Aaron C. Smith, Lee M. Stunkard, Yeyun Zhou, Paul R. Carlson, Scott W. Niman, Patrick J. Sutter, John I. Trujillo, Logan E. Vine, Brooklynn Venteicher
  • ERBB2 INHIBITORS
    Publication number: 20250129078
    Abstract: A compound having the following structure of Formula (I): or a stereoisomer of the compound, pharmaceutically acceptable salt, or tautomer thereof, wherein E, L, R3a, R3b, R3c, R3d, R5b, R8, Y1, Y2, Y3, Y4, Y5, Y6, X1, X2, Z1, and Z2 are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Application
    Filed: April 10, 2024
    Publication date: April 24, 2025
    Inventors: Leah J. Salituro, Jennifer Fulton, Ravi Kumar Jalluri, Logan E. Vine, Tanna Bettendorf, John Fischer, Jay B. Fell, Mark J. Chicarelli, Payal Chatterjee, Cori A. Malinky
  • PI3K inhibitors
    Patent number: 12281122
    Abstract: A compound having the following structure of Formula (I): or a stereoisomer of the compound, tautomer of the compound, pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, A, X, Z, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Grant
    Filed: August 5, 2024
    Date of Patent: April 22, 2025
    Assignee: COGENT BIOSCIENCES, INC.
    Inventors: Payal Chatterjee, Mark J. Chicarelli, Michael L. Conner, John Fischer, Jennifer Fulton, Ravi Kumar Jalluri, Hailey J. Knox, Vijay Kumar, Bradley J. Newhouse, Martha E. Rodriguez, Leah J. Salituro, Aaron C. Smith, Lee M. Stunkard, Yeyun Zhou, Paul R. Carlson, Scott W. Niman, Patrick J. Sutter, John I. Trujillo, Logan E. Vine, Brooklynn Venteicher
  • COMPOUNDS FOR FGFR INHIBITION
    Publication number: 20250066352
    Abstract: A compound having the following structure of Formula (IV): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R3, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Application
    Filed: August 19, 2024
    Publication date: February 27, 2025
    Inventors: Jay Bradford Fell, John E. Robinson, John P. Fischer, Logan E. Vine, Martha E. Rodriguez, Jennifer Fulton, Tanna Bettendorf, Bradley J. Newhouse, Robert A. Rieger, Cori A. Malinky, Aaron Christopher Smith, Ravi Kumar Jalluri, Mark Joseph Chicarelli, Leah J. Salituro, Macedonio J. Mejia
  • COMPOUNDS FOR FGFRS INHIBITORS
    Publication number: 20240270741
    Abstract: A compound having the following structure of Formula (I): or a stereoisomer, salt, or tautomer thereof, wherein R1, R2, R5, A, B, X, and Y are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
    Type: Application
    Filed: January 9, 2024
    Publication date: August 15, 2024
    Inventors: Jay Bradford Fell, John E. Robinson, John P. Fischer, Logan E. Vine, Martha E. Rodriguez, Jennifer Fulton, Tanna Bettendorf, Bradley J. Newhouse, Robert A. Rieger, Cori A. Malinky, Aaron Christopher Smith, Toya D. Scaggs, Joshua Dahlke, Ravi Kumar Jalluri, Mark Joseph Chicarelli, Leah J. Salituro, Macedonio J. Mejia, Payal Chatterjee
  • TERTIARY ALCOHOLS AS PI3K-y INHIBITORS
    Publication number: 20240228498
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: February 1, 2024
    Publication date: July 11, 2024
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • Tertiary alcohols as PI3K-? inhibitors
    Patent number: 11926630
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: March 12, 2024
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • Heterocyclic compounds as PI3K-? inhibitors
    Patent number: 11773102
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: October 3, 2023
    Assignee: Incyte Corporation
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20230009843
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 12, 2023
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • TERTIARY ALCOHOLS AS PI3K-y INHIBITORS
    Publication number: 20220213107
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: November 30, 2021
    Publication date: July 7, 2022
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • Tertiary alcohols as PI3K-? inhibitors
    Patent number: 11225486
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: January 18, 2022
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • Heterocyclic compounds as PI3K-y inhibitors
    Patent number: 11091491
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: August 17, 2021
    Assignee: Incyte Corporation
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • TERTIARY ALCOHOLS AS PI3K-y INHIBITORS
    Publication number: 20200385392
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: June 26, 2020
    Publication date: December 10, 2020
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • Tertiary alcohols as PI3K-? inhibitors
    Patent number: 10738057
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: August 11, 2020
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20200031837
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 1, 2019
    Publication date: January 30, 2020
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • Heterocyclic compounds as PI3K-? inhibitors
    Patent number: 10472368
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: November 12, 2019
    Assignee: Incyte Corporation
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • TERTIARY ALCOHOLS AS PI3K-y INHIBITORS
    Publication number: 20190152975
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: October 17, 2018
    Publication date: May 23, 2019
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue